Compile Data Set for Download or QSAR
maximum 50k data
Found 198 Enz. Inhib. hit(s) with all data for entry = 1457
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323806(US10189809, Compound I-1)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323807(US10189809, Compound I-3)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323808(US10189809, Compound I-26)
Affinity DataEC50:  8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323809(US10189809, Compound I-27)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323810(US10189809, Compound I-33)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323811(US10189809, Compound I-42)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323812(US10189809, Compound I-45)
Affinity DataEC50:  8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323813(US10189809, Compound I-4)
Affinity DataEC50:  8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323814(US10189809, Compound I-49)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323815(US10189809, Compound I-55)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323816(US10189809, Compound I-6)
Affinity DataEC50:  5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323817(US10189809, Compound I-61)
Affinity DataEC50:  5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323818(US10189809, Compound I-66)
Affinity DataEC50:  8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323819(US10189809, Compound I-71)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323820(US10189809, Compound I-72)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323821(US10189809, Compound I-75)
Affinity DataEC50:  5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323822(US10189809, Compound I-83)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323823(US10189809, Compound I-84)
Affinity DataEC50:  5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323824(US10189809, Compound I-85)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323825(US10189809, Compound I-86)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323826(US10189809, Compound I-87)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323827(US10189809, Compound I-92)
Affinity DataEC50:  5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323828(US10189809, Compound I-93)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323829(US10189809, Compound I-96)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM50175274(CHEMBL3809864 | US10189809, Compound I-97)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323831(US10189809, Compound I-98)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323832(US10189809, Compound I-99)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323833(US10189809, Compound I-100)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323834(US10189809, Compound I-101)
Affinity DataEC50:  5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323835(US10189809, Compound I-102)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323836(US10189809, Compound I-103)
Affinity DataEC50:  5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323837(US10189809, Compound I-104)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323838(US10189809, Compound I-105)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323839(US10189809, Compound I-106)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323840(US10189809, Compound I-107)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323841(US10189809, Compound I-108)
Affinity DataEC50:  2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323842(US10189809, Compound I-109)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323843(US10189809, Compound I-110)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323844(US10189809, Compound I-111)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323845(US10189809, Compound I-112 | US10189809, Compound ...)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323846(US10189809, Compound I-113)
Affinity DataEC50:  8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323847(US10189809, Compound I-114)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323848(US10189809, Compound I-115)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323849(US10189809, Compound I-116)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323850(US10189809, Compound I-118)
Affinity DataEC50:  8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323851(US10189809, Compound I-119)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323852(US10189809, Compound I-121)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323853(US10189809, Compound I-122)
Affinity DataEC50:  3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323854(US10189809, Compound I-125)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM323855(US10189809, Compound I-126)
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 198 total ) | Next | Last >>
Jump to: